POPULARITY
3 episodes with Pharmacodynamics
3 episodes with Pharmacodynamics
2 episodes with Pharmacodynamics
2 episodes with Pharmacodynamics
3 episodes with Pharmacodynamics
2 episodes with Pharmacodynamics
2 episodes with Pharmacodynamics
2 episodes with Pharmacodynamics
2 episodes with Pharmacodynamics
Send a textWe break down the mechanism of action for GLP-1 receptor agonists like tirzepatide (Zepbound/Mounjaro) and semaglutide, explaining how these medications work in the body to regulate appetite and metabolism.• GLP-1 medications contain a C20 fatty diacid that binds to albumin, prolonging half-life• These drugs target both GIP and GLP-1 receptors to regulate appetite and caloric intake• Receptors are found in brain areas involved in appetite regulation and throughout the GI system• Pharmacodynamics include increased insulin sensitivity, reduced glucagon secretion, and delayed gastric emptying• Medications are absorbed subcutaneously with about 80% bioavailability • Distribution occurs throughout the body with 5-6 day half-life, explaining weekly dosing• Metabolism occurs primarily through the liver with excretion via urine• Common injection sites include arms, legs, stomach, or back (the "margarita" zones)Never do this on your own without real supervision. Everything has to be done safely, with a healthcare provider and someone that is aware of where you stand and how you are. Support the show Sponsor Affiliates Empowering Your Health https://www.atecam.com/ Get YOUR Own Joburg Protein Snacks Discount Code: Damaris15 Or Damaris18 Feeling need to Lose Weight & Become metabolically Healthy GET METABOLIC COURSE GLP 1 REseT This course is designed for individuals looking to optimize their metabolic health through integrative and functional medicine approaches. Whether you're on a GLP-1 medication or seeking natural ways to enhance your metabolic function, this course provides actionable steps, expert insights, and a personalized roadmap sustainable wellness. Are you feeling stressed, tired, or Metabolism imbalanced? Take advantage of our free mindful steps to help improve your well-being.ENJOY ONE OF our Books Mindful Ways Health Wealth & Life https://stan.store/Mindfullyintegrative Join Yearly membership ALL IN ONE FUNCTION HEALTH Ask Us for help...
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
This is section 1.3 of the nearly 20-hour Nursing Pharmacology Review Course from Meded101! Enjoy! Pharmacodynamics is the “why” behind what medications do in the body—and for nurses, understanding it is key to safe and effective patient care. From receptor binding and dose–response relationships to therapeutic effects and adverse reactions, pharmacodynamics helps explain how medications produce both benefit and harm. In this episode, we'll break down pharmacodynamics in a practical, nurse-focused way, connecting core concepts to real bedside decisions. Whether you're titrating a medication, monitoring for side effects, or educating patients, this discussion will help you see how pharmacodynamics guides everyday nursing practice. Find access to the review course at meded101.com/nurse
In this episode, we review the high-yield topic of Pharmacodynamics from the Pharmacology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
For a captioned version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-15-pkpd-drug-discovery/In this episode of the Pharmaron DMPK Insights Podcast Series, Simon Taylor and Dr. Emile Chen discuss the relationship of drug concentration and effect (PKPD). PKPD is critical to decision making from initial modality selection, through molecule optimization, translational science and clinical dosage planning. Simon and Emile discuss the concepts and practical applications of PKPD and explore the concept of model-based target pharmacology assessment in combination with physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) modelling to improve decision making.** Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery”, J Med Chem. 2021 Mar 25;64(6):3185-3196. We will address the following points: What is PKPD and its importance throughout a discovery project lifecycle How PKPD can be used to guide decision making including case study examples How a combination of physiologically based pharmacokinetic/ pharmacodynamic (PBPK/PD) modeling and machine learning (ML) can be used to elucidate the optimal combination of properties for the targeted pharmacology Our Moderator:Simon Taylor – Vice President, Drug Discovery at Pharmaron Simon Taylor is Vice President of Drug Discovery and is based in Hoddesdon, UK. With over 27 years of industry experience, he is responsible for DMPK/ADME and PKPD strategy, including human extrapolation and PBPK modelling and simulation, for Pharmaron's integrated drug discovery projects from early discovery through to IND submission. Before Pharmaron, Simon worked at GSK for 20 years, leading DMPK and Quantitative Pharmacology teams and projects from the Hit Identification stage through to the clinic. He has worked across respiratory, inflammation, oncology, and cardiovascular therapy areas with drugs of varying routes of administration. Simon has a BSc in Pharmacology from the University of Leeds and an MSc in Model Based Drug Development from the University of Manchester. He has co-authored over 30 scientific publications in the literature. Our Speakers:Dr. Emile Chen – Formerly Director, Modeling and Translational Biology at GlaxoSmithKline Dr. Emile Chen has thirty years of industrial experience divided between early discovery involved in lead optimization and candidate selection, and late-stage development, including authoring and reviewing of regulatory documentation and NDA submission. Until March 2024, he was in the System Modeling and Translational Biology group, using PBPK, Mechanistic PKPD modeling, QSP, and machine learning techniques to solve project questions and thereby enhance scientific productivity. Emile received his undergraduate degree from the University of California, Los Angeles, and his PhD from Northwestern University in the field of Biomedical Engineering, specializing in the development of mathematical models for information processing in the brain. He began his pharmaceutical career at Hoffmann-La Roche in 1993, following a postdoctoral fellowship at the University of California, San Francisco. He joined GlaxoSmithKline in 1996. Over the years, he has led ADME and PK groups at various times, supporting both early discovery and late development DMPK efforts. More recently, rStay tuned for more podcasts in our Pharmaron DMPK Insights Series!
Dhineli Perera talks to pharmacists Amy Legg and Tony Lai about their paper on the safe and effective use of vancomycin. They discuss the evolution of vancomycin therapeutic drug monitoring, including trough concentrations, and demystify AUC monitoring. They cover current recommendations, including targets for drug efficacy and safety, and priority patient groups. Read the full article by Amy, Tony, and their co-authors, in Australian Prescriber.
In this episode of Onc Now, Jonathan welcomes Ahmad Awada, Head of the Oncology Department at Chirec Cancer Institute in Brussels and Editor in Chief of EMJ Oncology. Together they discuss groundbreaking developments in cancer care, the promise of targeted therapies, and the importance of global collaboration in oncology. Timestamps: (00:00)-Introduction (01:20)-Reflecting on ESMO 2024 (07:37)-Looking ahead to ESMO 2025 (10:04)-Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates (13:24)-New cytotoxics and molecular targeted therapies for solid tumours (16:30)-Surgery of primary tumour in de novo metastatic breast cancer (19:29)-Improving survival in cancer patients (22:47)-Managing the risk of thromboembolism (24:43)-Exciting advancements on the horizon (29:38)-Wishes for oncology
Drs. Anne-Grete Märtson, Megan Wimmer, and Evan Clemens join Dr. Erin McCreary to tackle the one of the hottest debates among providers taking care of immunocompromised patients, valganciclovir dosing! Learn all about the history of valganciclovir dosing, what is valganciclovir's PK/PD target, and even valganciclovir therapeutic drug monitoring. References: Märtson AG, Edwina AE, Kim HY, Knoester M, Touw DJ, Sturkenboom MGG, Alffenaar JC. Therapeutic Drug Monitoring of Ganciclovir: Where Are We? Ther Drug Monit. 2022 Feb 1;44(1):138-147. doi: 10.1097/FTD.0000000000000925. PMID: 34610621; PMCID: PMC8746890. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP; Valganciclovir Solid Organ Transplant Study Group. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005 Jun 15;79(11):1477-83. doi: 10.1097/01.tp.0000164512.99703.ad. PMID: 15940035. This podcast is powered by Pinecast.
In this episode, Ayesha spoke with Howard McLeod, PharmD, Director of the Center for Precision Medicine and Functional Genomics, Professor of Pharmacy and Medicine at Utah Tech University and Precision Medicine Advisor at the Geriatric Oncology Consortium; and Sharmeen Roy, PharmD, Chief Strategy and Science Officer at DoseMe, which is the world's first and largest Bayesian dosing platform designed for clinical practice.Precision dosing, also known as personalized dosing, aims to tailor drug dosages to the individual characteristics of each patient to achieve optimal therapeutic outcomes while minimizing adverse effects. It leverages various patient-specific factors, including genetics, age, weight, organ function and even lifestyle, to determine the most appropriate dosage for each individual. Dr. McLeod is an internationally recognized expert in precision medicine, who has made novel contributions at the discovery, translation, implementation and policy levels. Dr. McLeod received his Doctorate in Pharmacy from the Philadelphia College of Pharmacy and Science and completed his Post-Doctoral Training at St Jude Children's Research Hospital and the University of Glasgow. Dr. Roy is passionate about leveraging technology to amplify the impact of the pharmacist. Her career spans pediatric clinical pharmacy, clinical research and pharmacogenomics with leadership roles at University of Chicago Medical Center and PipelineRx. She received her Doctor of Pharmacy degree from the University of Illinois at Chicago, is a Board-Certified Pharmacotherapy Specialist and completed a Pediatric Specialty Pharmacotherapy Residency at Texas Children's Hospital.Tune into the episode to learn more about the current landscape of precision dosing, including the latest technologies and tools designed to help optimize drug dosages.For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social MediaTwitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
We have recently been asked the question, "Are all AAS equal on a mg/mg basis?" Today, Dr Scott Stevenson explores this topic in this lecture. With Scott McNally TIME STAMPS BELOW - Muscle Minds Podcast 156 0:00 Teaser 0:45 Intro 1:30 Are All Steroids Equally Anabolic? 2:30 What is the question exactly? 6:20 Why ask the question? 12:20 Is it likely that all AAS are equal on a mg/mg basis 25:20 Pharmacogenetics and Pharmacodynamics 31:40 AAS Data in Humans 41:30 Supra physiological Test Study 43:50 Deca Study 51:45 Study comparison of multiple AAS 1:05:20 What can we make of this? 1:07:30 Practical dose response curves 1:15:00 Concluding Thoughts on AAS Anabolic Equivalency 1:19:00 Amazing Dog Pics!!
This week we review an episode from 2022 in the world of cardiac surgery and pediatric pharmacology when we review a work from Australia on levels of cefazolin during and after surgery. Is there an optimal dose regimen that will achieve proper MIC levels of drug? What should the goal of therapy be in regards to MIC levels? Are there novel means of dosing cefazolin? We speak with pediatric critical care pharmacy coordinator at Mount Sinai Kravis Children's Hospital, Dr. Jessica Frye for the pharmacist's perspective on some of these important questions.https://doi.org/10.1016/j.athoracsur.2022.02.047
Unit 1 Kinetics and Dynamics 1_7 Pharmacodynamics This is a free open educational resource I am reading as an audio to make more accessible under Creative Commons Attribution 4.0 International License. While I am a licensed pharmacist, I am not providing any health advice, this is for educational purposes only. Here's my website: https://www.memorizingpharm.com/ Where you can get the Memorizing Pharmacology: A Relaxed Approach audiobook, possibly for free: https://www.audible.com/pd/Memorizing-Pharmacology-Audiobook/B09JVBHRXK?source_code=AUDFPWS0223189MWT-BK-ACX0-281667&ref=acx_bty_BK_ACX0_281667_rh_us OER Pharmacology Book Link to download or view the book presented in the video. https://wtcs.pressbooks.pub/pharmacology/ Want to get in touch with me, tonythepharmacist@gmail.com
More information about Brain Lenses at brainlenses.com.BL supporters receive an additional episode of the show each week. Info about becoming a supporter at the above address, or at Understandary.com.Read the written version of this episode: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit brainlenses.substack.com/subscribe
Understanding a novel drug's PK and PD properties begins with nonclinical studies and evolves through early phase clinical trials. In this issue, we take a closer look at the collection and use of PK/PD data in early phase drug development. CHAPTERS: - 0:08 — Introduction to Issue 34 - 1:32 — Nonclinical Studies - 2:39 — IND Requirements and Translation to Clinical PK/PD - 5:37 — Translating Nonclinical Knowledge of PK/PD Analyses to Clinical Study - 8:51 — Case Study - 12:32 — Conclusion Click here to read Issue 34: https://www.altasciences.com/sites/default/files/2023-08/the-altascientist-issue-34-toxicokinetics-pharmacokinetics-and-pharmacodynamics.pdf Introduction on TK, PK, and PD Data: The understanding of a new drug's absorption, distribution, metabolism, and excretion (more commonly known as ADME) is critical to ensure that it is safe for human use. That understanding is achieved through collection and analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data, which together account for approximately 25% of the contents of a drug package insert or label. The characterization of PK/PD effects starts with nonclinical toxicokinetic (TK) studies in animals. The purpose of TK studies is to define the chemical properties of the drug, including pharmacology and toxicology, and to assist in development of downstream clinical protocols. The necessary nonclinical studies are conducted before submission of Investigational New Drug (also known as IND) applications to the FDA or other global regulatory agencies, and deliver critical data used to set the parameters for future clinical trials. About Altasciences: Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” For helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast.
Free pharmacology audiobook if you've never had one with Audible before: https://www.audible.com/pd/Memorizing-Pharmacology-Audiobook/B09JVBHRXK?source_code=AUDFPWS0223189MWT-BK-ACX0-281667&ref=acx_bty_BK_ACX0_281667_rh_us These two words, pharmacokinetics, and pharmacodynamics, get confused; I wanted to put up a quick way to remember the difference. If you want a longer explanation, go to episode 21, pharmacology basics, in the NGN NCLEX Memorizing Pharmacology Playlist.
Understanding how living cells work is difficult due to the number of varied and complex processes occurring in them. This complexity can be elucidated by breaking these processes down and focusing on a particular mechanism. One approach is to use mathematical equations – the basis of computational modelling. Dr Susan Mertins, the founder and CEO of Biosystem Strategies LLC, in the USA, is exploring how ordinary differential equations and machine learning can be applied to cancer data for biomarker discovery and drug development, leading to improvements in personalised medicine.Read more in Research OutreachRead some of their latest work here: https://doi.org/10.3389/fonc.2021.805592
In this episode, Jonathan is joined by Joubert Gama, a Medical Consultant in the pharmaceutical industry. They discuss their experiences in medical school which they attended together, and Gama provides insights as to what attracted him to working in the pharmaceutical industry with an emphasis on drug development, pharmacodynamics, and clinical affairs including medical regulations and compliance. Gama takes us on a journey of what it takes to bring a drug to market, as well as delving into his surprising appearances on well-known several television series!
https://www.patreon.com/theemttutor This lecture/podcast is part of the Pharmacology Block series. By the end of this lecture, the student should have an understanding of the following: Knowledge Domains: Define the following key terms: Pharmacodynamics, Intended Effects, Indications, Side Effects, Unintended Effects, Untoward Effects, Contraindications Generic versus Trade name medication Enteral versus Parenteral medications Routes of medication administration: Rectal, Oral, Intravenous, Intraosseous, Subcutaneous, Intramuscular, Inhalation, Sublingual, Transcutaneous Forms of medications: Solid, Liquid, Gas The Six Rights of Medication Administration Direct Orders versus Standing Orders Peer-assisted, Patient-assisted and EMT-administered medications Medications used by EMTs – Lecture 1 of the Pharmacology Block Medications administration to pediatrics, geriatrics, and pregnant patients Steps for auto-injector Understanding patient medications (prescribed and OTC) Medication Errors --- Send in a voice message: https://anchor.fm/thepublicsafetyguru/message
Austin Morrison, Infectious Diseases and Antimicrobial Stewardship Clinical Pharmacist at the Moffitt Cancer Center and Research Institute, presents a talk on the pharmacokinetic and pharmacodynamic principles associated with the optimal dosing of antimicrobial agents. Dr. Morrison begins by defining basic antimicrobial concepts, including absorption, distribution, metabolism, and excretion. He then compares and contrasts concentration-dependent versus time-dependent killing as it applies to different antimicrobial classes. Dr. Morrison then specifically singles out beta-lactams and time-dependent killing and the benefits of extended dosing strategies. He also discusses the significance of the AUC/MIC curve. Lastly, Dr. Morrison concludes by discussing antibiotic dosing in renal insufficiency and the ideal strategies for this group of patients.
Pharmacodynamics, medication actions at receptors.
Go to sleep but what else?
Visit https://thermofisher.com/bctl to register for your free Bringing Chemistry to Life T-shirt and https://www.thermofisher.com/chemistry-podcast/ to access the extended video version of this episode and the episode summary sheet, which contains links to recent publications and additional content recommendations for our guest. You can access the extended video version of this episode via our YouTube channel to hear, and see, more of the conversation!Antibiotics are an incredibly important class of drugs and possibly the most impactful, life-changing scientific innovation in history. However, microorganisms reproduce themselves very rapidly and can evolve in literal minutes. We can't iterate science this quickly, which is the basis of increasing cases of antibiotic resistance that are a growing concern in modern medicine. Antibiotics are complex both chemically and in their biological function, which makes them hard to develop and a relatively unattractive pharmaceutical class from the business perspective. Like never before, we need a fresh perspective, and this is where Ziyang Zhang is leaving an impression. Ziyang is young, but incredibly productive and creative. Even before starting with his own research group (soon at Berkley), he has achieved so much and shown incredible chemical talent and thinking unlike anyone else's. His new way of thinking can affect drug development strategies for antibiotics and beyond.This is a captivating discussion with an incredible character, that fascinates with his understated style as he introduces us to his chemistry and his ideas. In a classic BCTL way, we explore his personal and professional path, his research into macrolide antibiotics, and his novel approach to selectively targeting brain cancer.
In this episode, we review the high-yield topic of Pharmacodynamics from the Pharmacology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficialx Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message
In this episode, Fidelia Bernice, PharmD, and Jennifer Cocohoba, PharmD, share insights on new HIV data from CROI 2022, including:Islatravir tissue and plasma distribution after monthly oral dosingPharmacokinetics, safety, and acceptability of a tenofovir vaginal ringPrEP and Hormone Therapy in Transgender IndividualsAnticholinergic drug effects in older PWHAdherence in PWHPresenters:Fidelia Bernice, PharmDClinical Pharmacy Specialist, Infectious DiseasesDepartment of PharmacyUniversity of Maryland Medical CenterBaltimore, MarylandJennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program:https://bit.ly/3tdkXfJ
We're kicking off a new multi-part series focusing on the pharmacology of cannabis.We're kicking off a new multi-part series focusing on the pharmacology of cannabis.Maybe it's been a while since you were in med school, or you've never been! So in this first episode, we'll focus on the basics of pharmacokinetics (PK), pharmacodynamics(PD), the downstream effects of stimulation, and how that affects the overall function of the endocannabinoid system (ECS).
We're kicking off a new multi-part series focusing on the pharmacology of cannabis.Maybe it's been a while since you were in med school, or you've never been! So in this first episode, we'll focus on the basics of pharmacokinetics (PK), pharmacodynamics(PD), the downstream effects of stimulation, and how that affects the overall function of the endocannabinoid system (ECS).
We're kicking off a new multi-part series focusing on the pharmacology of cannabis.Maybe it's been a while since you were in med school, or you've never been! So in this first episode, we'll focus on the basics of pharmacokinetics (PK), pharmacodynamics(PD), the downstream effects of stimulation, and how that affects the overall function of the endocannabinoid system (ECS).
Show Notes for Episode Twenty of seX & whY: Interview With Dr Shirin Heidari Part 2: Gendro - Advancing Sex and Gender Equity in Science Research Host: Jeannette Wolfe Guest: Shirin Heidari PhD, virologist and experimental oncologist, founding President of Gendro. Part 2 of Interview with Dr Shirin Heidari This podcast focuses on Dr Heidari's work on systematically integrating the variables of sex and gender into different access points along the research pipeline. She helped start an organization called Gendro which is dedicated to this mission. The three major gatekeeping posts that Gendro and other organizations are targeting are: 1) Funding Require the inclusion of both male and female animals or justify an exclusion 2) Ethical Review Boards These boards review research protocols prior to study enrollment to ensure that the researchers have designed their study to meet national and organization protocols designed to protect participants from being involved with unethical or dangerous practices. Traditionally these boards have been an overlooked area to target. 3) Journals As many medical publishing house multiple journals, if they modify their standardized template to include query about sex and/or gender analyses, they have the power to rapidly change the expectations of authors and peer reviewers surrounding the inclusion of these factors. In addition, we talked about the SAGER guidelines SAGER guidelines a.k.a. Sex and Gender Equity in Research. These guidelines were put together by an international team of researchers in 2015 and geared towards giving researchers, journal editors, peer- reviewers and publishers better tools to include and evaluate the variables of sex and gender in scholarly work. Although the guidelines have increased the awareness and inclusion of these variables, and many journals have now adopted them, there continues to be a significant opportunity for more widespread use. A recent editorial highlights some of the barriers to utilization and possible concerns. Here is a synopsis of some of the remaining barriers. Perceived Barrier Solution Mandated inclusion will significantly increase overall research costs from enrollment to additional statistical analysis Underscore that several countries have already been successful in tying initial funding with inclusion criteria which suggests that some of resistance is likely due to ingrained culture rather than significant financial barriers. Highlight that some countries have developed new supplemental funding to enhance adoption. * Journal editors may have significant time and resource limitations that prohibit their ability to formally introduce or monitor SAGER guidelines. Emphasize that optimizing science requires constant evolution and that as editors they are already well skilled in helping their journal comply with other required updates. Including SAGER guidelines can enhance the quality of research their journal publishes and in turn enhance its reputation. In additional, engaging publishers to invest in better science by making system wide changes in both editorial expectations and technical support (see below) could rapidly accelerate adoption. Peer reviewers may feel ill-equipped to evaluate for the proper inclusion of sex and gender in a review due to knowledge gaps in core principles surrounding sex and gender Provide access to available online trainingmodules such as those offered by the Canadian Institutes of Health Research. Enhance diversity training as who is at the table influences policy and priorities. Technical challenges. Many publishers use the same templates across multiple journals which may limit an individual journal's ability to change their own format. Engage editors to encourage publishers to update digital templated formatting to reflect SAGER principles. The inclusion of a requested digital check off page in submission requirements confirming guideline compliance, could serve both as a reminder cue to the author and a screening tool to journal staff to ensure that it is completed prior to forwarding material to reviewer. This would help minimize any additional time the reviewer would need to spend to ensure SAGER compliance. * As an aside, identifying important sex-based differences in pre-clinical studies may ultimately be quite cost effective as they may lead to the design of more successful and cost-effective clinical trials We also discovered the opportunities to include the variables of sex and gender in COVID vaccine research and here are two important papers that Dr Heidari just published in this area. A Systemic Review of the Sex and Gender Reporting in Covid-19 Clinical Trials. 75 initial published trials- 24% presented data broken down by sex and only 13% included in their discussion any discussion about potential sex differences. Time for Action: towards an intersectional gender approach to COVID-19 vaccine development and deployment that leaves no one behind. Take home points from article sex and age-based differences in immunology may influence vaccine dosing/side effects sex based differences may influence gendered associated acceptance and uptake of vaccines (for example if it is known that women get more side effects with a vaccine it may influence another women's readiness to get vaccinated.) sociocultural associated factors can influence vaccine acceptance and uptake it is critical to have meaningful inclusion of gender diverse voices in high level research and policy decisions. This now becomes very relevant as we now know that there are significant sex differences in side effects in the vaccines including increased risk of myocarditis for males in Pfizer and Moderna (According to a recent Australian study done by their equivalent of the FDA, the Therapeutic Goods Administration (TGA) numbers may occur up to 1 in 10,000 in younger men. Of note, they suggest that chance of getting myocarditis from Covid is likely 8-10x this risk.) Conversely women are more likely to get increased risk of clotting with the J and J vaccine. Thanks for joining us!
When administering medications to special populations there are certain considerations that the nurse should be aware of. In this episode, we will explore how some normal processes of aging can affect our patients' pharmacokinetics and pharmacodynamics as well as other important consideration when administering medications to the geriatric population.
Healthcare Professionals Resiliency and Vaccine HesitancyAs the COVID-19 pandemic rages on, healthcare professionals across the nation continue to face extreme challenges as they battle on the frontlines. The mental and emotional toll this pandemic is taking on care providers is enormous. As such, the resiliency of healthcare professionals has come into focus. Organizations are striving to provide support for staff, and reduce the mental and emotional stressors associated with providing care during the pandemic. How can healthcare professionals more effectively deal with the everyday stressors they encounter? How can facilities prioritize the well-being and resiliency of healthcare professionals in the face of the ongoing pandemic? What strategies can healthcare professionals employ in their practice to best care for patients who may be experiencing vaccine hesitancy?Join host Lauren Sauer, and special guests Jacinda Abdul-Mutakabbir, Precious Davis, and Dr. Jasmine Marcelin on this episode of Transmission Interrupted as they discuss topics surrounding healthcare professionals, resiliency and vaccine hesitancy through the lens of the COVID-19 pandemic.Questions or comments for NETEC? Contact us: info@netec.orgFind us on the web: netec.orgGuestsJacinda Abdul-Mutakabbir, PharmD, AAHIVPJacinda Abdul-Mutakabbir is an Assistant Professor of Pharmacy Practice at Loma Linda University. She recently completed her post-graduate fellowship training at the Anti-Infective Research Laboratory at Wayne State University, Detroit, MI, where she will also receive her MPH. She is a graduate of University of Saint Joseph School of Pharmacy and completed her PGY1 Pharmacy Practice Residency as well as her undergraduate studies at Howard University. Dr. Abdul-Mutakabbir's research and practice interests include Pharmacokinetics and Pharmacodynamics of combination therapy in antimicrobial resistant infections, antimicrobial stewardship, and optimal care for people with HIV. In early 2020 she was recognized among the ECCMID “30 under 30” Outstanding Young Scientists in which she was quoted “as a minority woman researcher, I have worked ardently to promote the necessity of women of color in the research arena.” Dr. Abdul-Mutakabbir is an active member of AAHIVM, IDSA, and ASHP and was the chartering president of the Zeta Iota chapter of Kappa Psi at the University of St. Joseph. She joined SIDP as a trainee and looks forward to a long and successful career of practice, research and service in infectious diseases pharmacotherapy. Precious Davis, BSN, MSNPrecious Davis received her Bachelors of Science in Nursing from Nebraska Wesleyan University in 2015, and received her Masters of Science in Nursing Education from Western Governors University in Utah. She previously worked as a nurse at ENCOR/ENHSA managing the care of individuals with developmental disabilities and supervising nursing assistants and medication aides. Precious has worked as a case manager/staff nurse coordinating patient care for high-risk, complex patients at Nebraska Medicine, and recently started working as a nurse case manager at the Specialty Care Center in January 2017.Jasmine Marcelin, MDDr. Marcelin is a Caribbean native born on the island of Dominica. She received her Bachelor of Science degree with a double major in Biology and Chemistry, and a Diploma in Forensic Science at St. Mary's University in Halifax Nova Scotia. She then returned to her second home, Antigua & Barbuda, for medical school at American University of Antigua College of Medicine, after which she then completed Internal Medicine residency followed by Infectious Diseases fellowship at Mayo Clinic in Rochester, Minnesota. During her time at Mayo...
Pharmacokinetics- pharmacodynamics, pharmacogenetics with a nursing twist.
Show Notes for Episode Twenty of seX & whY: Interview With Dr Shirin Heidari Part 1: Sex and Gender Variables in Science Research Host: Jeannette Wolfe Guest: Shirin Heidari PhD, virologist and experimental oncologist, founding President of Gendro. Part 1 of this podcast spotlights the opportunity to do better science by paying more attention to the variables of sex and gender. Many times, we simply assume that when we study a medical question in a clinical trial that who is in the trial, adequately represents the population of folks who are affected by the condition being studied. When it comes to the consideration of gender, often this is not true. Dr Heidari and her team did a systemic review that evaluated study participant's gender in HIV research trials, although more than 50% of people who have HIV are women, only 19% of participants in anti-retroviral trials were women. In 1993 the NIH passed the Revitalization Act in which NIH funded studies would be required to study both men and women. A parallel mandate for basic science research passed over 20 years later in 2015. In some ways this is incredibly nonsensical because most of medical research starts out in the basic science lab. If you don't include animals of both sexes, in adequate numbers, from the beginning, you could be later blindsided in an expensive clinical trial by a physiological sex-based differences that could have been picked up earlier. Even though there has been progress over the past 30 years, Dr Heidari repeatedly makes the case that just because there are guidelines to include males and females in trials, this does not mean that these guidelines are adhered to or adequately enforced. In addition, there is often a large divide between including men and women in a study and doing an appropriate analysis to see what happens to those men and women. Essentially including both men and women isn't all that helpful unless you breakdown your results also by gender. Importantly, the very best studies go even a step further - they include a calculation in the original study design to determine how many men and how many women would need to be included in a study so that if a difference is found that the researchers can be more confident that the difference represents a real finding and not a statistical blip. Another important point discussed, is the chance for skewing of study results if researchers don't consider the gender breakdown of who drops out of a trial. Although it is not uncommon for studies to have a small number of participants drop out (and this can happen for a bunch of different reasons ranging from side effects to an inconvenient study location) it is uncommon for them to report the gender breakdown of the dropouts. If significantly more women, or men, drop out of a trial this could be a red flag that something else might be going on and hint to potential problems with the study's conclusions. Our conversation then veered to discussing pharmacokinetics and pharmacodynamics. Pharmacokinetics tells us about how the body influences a drug - specifically how a drug gets absorbed, distributed, and metabolized. Pharmacodynamics, on the other hand, tells us how the drug influences the body. An example I like to use is to compare giving someone a medication to hiring a secret agent. In both cases, there is a break in, a job and an exit. Traditionally it was believed that, outside of extreme differences in body weight, that drugs worked similarly- break in/job/exit - in male and female bodies if the drug did not target a reproductive organ. We now know this default “no sex difference” assumption is not scientifically valid as there are many drugs which work differently in male and female bodies and that these differences have clinical relevancy. An example of this is a study we discussed on marijuana pharmacokinetics with women requiring far less amount of marijuana to experience the same cognitive effects. In the discussion section of this paper it suggests that previous studies may have under-appreciated this sex-based difference because they often had higher dropout rates in women which likely skewed their final study results. And here is the link to some of the material we discussed surrounding the knowledge gap on pregnancy and pot-smoking and how this gap has caused some pregnant women to reach out to non-traditional resources to get information. Other studies we mentioned Here is a study that suggests that the gender of the researcher or lab tech may subtly influence research results. Here is a study that suggests that male and female animals both have similar amounts of hormonal variation. In part two we will discuss possible solutions.
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.Well! Well! Well! This is the last episode of SEASON 1, and topic of the day is "Drug Antagonism" and YES! I kept my promise to talk about Affirmations for New Year too today!!Antagonism can be of many types like Chemical, Physiological and Pharmacological Antagonisms. Then I will also talk about subclassifications like Receptor Antagonism, Competitive, Non Competitive and their subtypes too!But mantra is to make strong Affirmations and try stick to them in 2022!!Talk to you all again with second saga/season of my podcast!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.Well! Well! Well! This is the last episode of SEASON 1, and topic of the day is "Drug Antagonism" and YES! I kept my promise to talk about Affirmations for New Year too today!!Antagonism can be of many types like Chemical, Physiological and Pharmacological Antagonisms. Then I will also talk about subclassifications like Receptor Antagonism, Competitive, Non Competitive and their subtypes too!But mantra is to make strong Affirmations and try stick to them in 2022!!Talk to you all again with second saga/season of my podcast!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. Well! Well! Well! This is the last episode of SEASON 1, and topic of the day is "Drug Antagonism" and YES! I kept my promise to talk about Affirmations for New Year too today!! Antagonism can be of many types like Chemical, Physiological and Pharmacological Antagonisms. Then I will also talk about subclassifications like Receptor Antagonism, Competitive, Non Competitive and their subtypes too! But mantra is to make strong Affirmations and try stick to them in 2022!! Talk to you all again with second saga/season of my podcast!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!! You can access various links via https://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.With a good gracious planning to wave 2021 a "CHAO", let us prepare well for new chores in n ew year 2022. In today's episode I will talk about Drug Synergism, its subheads, types, and I will also cover Drug Selectivity, specificity, Therapeutic efficacy, therapeutic Index, (T.I.) , Therapeutic range /Window. All will be clearly described with apt examples, hope you find this verbal talk beneficial!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.With a good gracious planning to wave 2021 a "CHAO", let us prepare well for new chores in n ew year 2022. In today's episode I will talk about Drug Synergism, its subheads, types, and I will also cover Drug Selectivity, specificity, Therapeutic efficacy, therapeutic Index, (T.I.) , Therapeutic range /Window. All will be clearly described with apt examples, hope you find this verbal talk beneficial!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. With a good gracious planning to wave 2021 a "CHAO", let us prepare well for new chores in n ew year 2022. In today's episode I will talk about Drug Synergism, its subheads, types, and I will also cover Drug Selectivity, specificity, Therapeutic efficacy, therapeutic Index, (T.I.) , Therapeutic range /Window. All will be clearly described with apt examples, hope you find this verbal talk beneficial!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!! You can access various links via https://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.With the winters setting. in, I will be beginning today's episode in a poetic way and finally I will be setting up introduction to Dose Response relation/curves. Today I will cover the shape, importance of log DRC and its significance. I will be discussing three important aspects in this context namely Drug Potency, Drug Efficacy and Slope of DRC with apt examples and descriptions.Finally with a little talk about my two new highlights and ventures, I will be winding my weekend discussions , hope you all like it!!My patreon page link: https://www.patreon.com/ispharmacology My teespring store: https://my-store-c35101.creator-spring.com/ For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.Today is a great Sunday as I am going to mark the end of receptor tale by discussing mainly two heads, namely No Receptor Mechanisms of Drug Action and also a few Receptor Pathologies. It will be a very informative talk and will be of great value at the same time great relief to pave the way to begin a new topic after today!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.Marking the beginnings of today's episode, narrating the glory and essence of a LIBRARY, I will be talking about the Regulation of receptors. I will thoroughly explain the terms up regulation and down regulation of receptors. I will also talk about connected terms like supersensitivity and desensitisation of receptors. Mechanism. consequences and examples of all these phenomena will be detailed. Hope you all find this episode of great importance and value.... For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.Marking the beginnings of today's episode, narrating the glory and essence of a LIBRARY, I will be talking about the Regulation of receptors. I will thoroughly explain the terms up regulation and down regulation of receptors. I will also talk about connected terms like supersensitivity and desensitisation of receptors. Mechanism. consequences and examples of all these phenomena will be detailed. Hope you all find this episode of great importance and value.... For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. Marking the beginnings of today's episode, narrating the glory and essence of a LIBRARY, I will be talking about the Regulation of receptors. I will thoroughly explain the terms up regulation and down regulation of receptors. I will also talk about connected terms like supersensitivity and desensitisation of receptors. Mechanism. consequences and examples of all these phenomena will be detailed. Hope you all find this episode of great importance and value.... For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!! You can access various links via https://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.HAPPY DIWALI TO ALL!!In today's episode , I will be talking about enzyme linked and JAK-STAT Transmembrane receptors along with cytoplasmic and nuclear receptors.Season 1 coming to end, BUTBOOK OF SEASON 1 IS ON AMAZONGet your copy at:E-BOOK: https://www.amazon.in/dp/B09KQP36CRPaperback: https://www.amazon.com/dp/B09KN7Y9LKHardcover: https://www.amazon.com/dp/B09KNCWP1DFor all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also.You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.HAPPY DIWALI TO ALL!!In today's episode , I will be talking about enzyme linked and JAK-STAT Transmembrane receptors along with cytoplasmic and nuclear receptors.Season 1 coming to end, BUT BOOK OF SEASON 1 IS ON AMAZONGet your copy at:E-BOOK: https://www.amazon.in/dp/B09KQP36CRPaperback: https://www.amazon.com/dp/B09KN7Y9LKHardcover: https://www.amazon.com/dp/B09KNCWP1D For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links viahttps://linktr.ee/ispharmacologydifficult
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. HAPPY DIWALI TO ALL!! In today's episode , I will be talking about enzyme linked and JAK-STAT Transmembrane receptors along with cytoplasmic and nuclear receptors. Season 1 coming to end, BUT BOOK OF SEASON 1 IS ON AMAZON Get your copy at: E-BOOK: https://www.amazon.in/dp/B09KQP36CR Paperback: https://www.amazon.com/dp/B09KN7Y9LK Hardcover: https://www.amazon.com/dp/B09KNCWP1D For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!! You can access various links via https://linktr.ee/ispharmacologydifficult
Details of drugs components
Pathopharmacology lecture 05/14
© 2020-2026 Ivy Podcast Discovery LLC
